Teacher Retirement System of Texas increased its holdings in shares of Balchem Corporation (NASDAQ:BCPC - Free Report) by 11.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,896 shares of the basic materials company's stock after purchasing an additional 3,695 shares during the period. Teacher Retirement System of Texas owned 0.11% of Balchem worth $5,793,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. KBC Group NV boosted its stake in shares of Balchem by 24.1% during the first quarter. KBC Group NV now owns 1,582 shares of the basic materials company's stock valued at $263,000 after purchasing an additional 307 shares in the last quarter. Yorktown Management & Research Co Inc bought a new position in shares of Balchem during the first quarter valued at approximately $241,000. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Balchem by 243.2% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,390 shares of the basic materials company's stock valued at $1,559,000 after purchasing an additional 6,654 shares in the last quarter. Cardinal Capital Management boosted its stake in shares of Balchem by 4.3% during the first quarter. Cardinal Capital Management now owns 25,842 shares of the basic materials company's stock valued at $4,290,000 after purchasing an additional 1,071 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its stake in shares of Balchem by 8.9% during the first quarter. QRG Capital Management Inc. now owns 5,645 shares of the basic materials company's stock valued at $937,000 after purchasing an additional 462 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors.
Balchem Price Performance
Shares of BCPC opened at $164.92 on Monday. The company has a market cap of $5.38 billion, a price-to-earnings ratio of 39.55, a price-to-earnings-growth ratio of 3.56 and a beta of 0.89. Balchem Corporation has a twelve month low of $145.70 and a twelve month high of $186.03. The company has a quick ratio of 1.40, a current ratio of 2.44 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average of $163.40 and a two-hundred day moving average of $163.03.
Balchem (NASDAQ:BCPC - Get Free Report) last announced its earnings results on Thursday, April 24th. The basic materials company reported $1.22 earnings per share for the quarter, missing the consensus estimate of $1.25 by ($0.03). The firm had revenue of $250.52 million during the quarter, compared to analyst estimates of $245.70 million. Balchem had a net margin of 14.16% and a return on equity of 12.01%. Balchem's revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business earned $1.03 earnings per share. As a group, analysts predict that Balchem Corporation will post 4.64 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on BCPC. HC Wainwright set a $180.00 price objective on shares of Balchem and gave the company a "buy" rating in a research note on Monday, April 28th. Wall Street Zen downgraded shares of Balchem from a "buy" rating to a "hold" rating in a research note on Wednesday, May 21st.
View Our Latest Stock Report on Balchem
Balchem Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Corporation (NASDAQ:BCPC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.